Q2 2026 13F · SEC CIK 2038158
NEXTBio Capital Management LP
Hedge fundFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗
- Reported 13F value
- $217.4M
- Reported positions
- 22
- Holdings vs S&P 500, 3 yrs
- —
- Assets under management
- $305.2M
NEXTBio Capital Management LP is a hedge fund that reported 22 positions worth $217.4M in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Protagonist Therapeutics Inc (PTGX, 12.4%), Shattuck Labs Inc (STTK, 11.9%), Compass Pathways PLC (CMPS, 11.6%).
NEXTBio Capital Management LP holdings all 22 positions.
Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.
| Stock | % of 13F value | Share change | Reported value |
|---|---|---|---|
| PTGXProtagonist Therapeutics Inc | 12.4% | -4.5% | $26.9M |
| STTKShattuck Labs Inc | 11.9% | +18.3% | $25.9M |
| CMPSCompass Pathways PLC | 11.6% | -12.2% | $25.1M |
| GPCRStructure Therapeutics Inc | 7.7% | +134.5% | $16.8M |
| VORVor Biopharma Inc | 7.5% | -11.1% | $16.4M |
| RYTMRhythm Pharmaceuticals Inc | 6.7% | +4.5% | $14.6M |
| PVLAPalvella Therapeutics Inc | 6.3% | +8.7% | $13.7M |
| XENEXenon Pharmaceuticals Inc | 5.1% | +0.0% | $11.1M |
| ZBIOZenas Biopharma Inc | 5.0% | +0.0% | $10.8M |
| ORICOric Pharmaceuticals Inc | 3.5% | +34.9% | $7.6M |
| IVAInventiva SACA | 3.1% | +34.1% | $6.8M |
| CBIOCrescent Biopharma Inc | 3.1% | +0.0% | $6.7M |
| PCVXVaxcyte Inc | 2.9% | +12.6% | $6.2M |
| COGTCogent Biosciences Inc | 2.3% | -0.1% | $5.1M |
| VSTMVerastem Inc | 2.3% | +0.0% | $5.0M |
| IRONDisc Medicine Inc | 1.8% | +0.0% | $3.9M |
| PHVSPharvaris N V | 1.7% | — | $3.7M |
| ZLABZai Lab Ltd | 1.6% | +0.0% | $3.5M |
| BIOABioage Labs Inc | 1.1% | — | $2.5M |
| LBRXLB Pharmaceuticals, Inc. | 1.0% | — | $2.2M |
| EVMNEvommune Inc | 0.7% | -35.3% | $1.6M |
| ACETAdicet Bio Inc | 0.6% | +0.0% | $1.4M |
What NEXTBio Capital Management LP bought and sold in Q2 2026, against Q1 2026.
New positions
- PHVS Pharvaris N V1.7% of 13F
- BIOA Bioage Labs Inc1.1% of 13F
- LBRX LB Pharmaceuticals, Inc.1.0% of 13F
Added to
- GPCR Structure Therapeutics Inc+134.5% shares
- ORIC Oric Pharmaceuticals Inc+34.9% shares
- IVA Inventiva SACA+34.1% shares
- STTK Shattuck Labs Inc+18.3% shares
- PCVX Vaxcyte Inc+12.6% shares
- PVLA Palvella Therapeutics Inc+8.7% shares
Reduced
- EVMN Evommune Inc-35.3% shares
- CMPS Compass Pathways PLC-12.2% shares
- VOR Vor Biopharma Inc-11.1% shares
Sold out
- TERN Terns Pharmaceuticals Incwas 14.8%
- CMPX Compass Therapeutics Incwas 2.1%
- OCS Oculis Holding AGwas 1.8%
- KALV Kalvista Pharmaceuticals Incwas 1.2%
- SMMT Summit Therapeutics Incwas 0.8%
Share counts compared with the Q1 2026 13F; a split also changes share counts.
How the holdings did against the S&P 500.
- 1 year
- —
- 3 years
- —
- 5 years
- —
A portfolio of the filer's 20 largest 13F positions, weighted by value and rebuilt each quarter on the day the filing became public. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.
Reported 13F value by quarter.
| Quarter | 13F value | Positions |
|---|---|---|
| Q2 2026 | $217.4M | 22 |
| Q1 2026 | $215.4M | 24 |
| Q4 2025 | $170.5M | 23 |
Questions about NEXTBio Capital Management LP's portfolio
What stocks does NEXTBio Capital Management LP own?
NEXTBio Capital Management LP's latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 22 positions worth $217.4M. The largest are Protagonist Therapeutics Inc (PTGX) at 12.4%, Shattuck Labs Inc (STTK) at 11.9%, Compass Pathways PLC (CMPS) at 11.6%, Structure Therapeutics Inc (GPCR) at 7.7% and Vor Biopharma Inc (VOR) at 7.5%.
What did NEXTBio Capital Management LP buy last quarter?
In Q2 2026, NEXTBio Capital Management LP added a new position in Pharvaris N V (PHVS), a new position in Bioage Labs Inc (BIOA), a new position in LB Pharmaceuticals, Inc. (LBRX), Structure Therapeutics Inc (GPCR) (+134.5% shares), Oric Pharmaceuticals Inc (ORIC) (+34.9% shares) and Inventiva SACA (IVA) (+34.1% shares), compared with its Q1 2026 filing.
What did NEXTBio Capital Management LP sell last quarter?
In Q2 2026, NEXTBio Capital Management LP sold all of Terns Pharmaceuticals Inc (TERN), sold all of Compass Therapeutics Inc (CMPX), sold all of Oculis Holding AG (OCS), sold all of Kalvista Pharmaceuticals Inc (KALV), sold all of Summit Therapeutics Inc (SMMT), Evommune Inc (EVMN) (-35.3% shares), Compass Pathways PLC (CMPS) (-12.2% shares) and Vor Biopharma Inc (VOR) (-11.1% shares), compared with its Q1 2026 filing.
When is NEXTBio Capital Management LP's next 13F filing due?
13F filings are due 45 days after each quarter ends. NEXTBio Capital Management LP's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.
How much money does NEXTBio Capital Management LP manage?
NEXTBio Capital Management LP reported $305.2M of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $217.4M.